The US government’s solution to the monkeypox vaccine shortage is so far only causing headaches for strained public health departments as the outbreak continues to grow in scale and scope.
The so-called dose-sparing strategy allows those giving out the vaccine to use just one-fifth of what’s traditionally given in attempt to squeeze more doses out of the existing supply. While sounding good in theory, the move requires “a significant shift in operations” for local health departments, Allison Arwady, Chicago’s public health commissioner, said during a Big Cities Health Coalition meeting. And it could be weeks before clinicians actually start employing this strategy, she said.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
FDA fast-tracks Eli Lilly's obesity candidate
Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.
Jefferies spots weaknesses in GN
One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.
Bavarian initiates new arm of phase III Covid-19 vaccine trial
The first patient has already been dosed in the US, and the Danish vaccine maker is now expanding the study to include Denmark and Belgium.
Life science CEOs' paychecks decrease as markets decline
When the markets are down, everyone is in the same boat, in theory -- however, former Ambu CEO Lars Marcher warns boards against unduly rewarding CEOs by changing pre-existing share-based programs.
Fujifilm doubles bottom line in annual report
Despite a 12.5% cost increase compared to the preceding year, Fujifilm Diosynth Biotechnologies managed to increase its profit twofold in 2021/2022.
KLIFO is looking for QA Specialist/Senior QA Specialist, GCP and GVP for our Glostrup office 
Senior CMC Regulatory Manager 
Analytical CMC Specialist 
Scientist Radiochemistry 
Chief Business Officer 
Drug Safety Associate 
CTM / Junior CTM Biotech 
Senior Drug Product Specialist 
Product specialist 
Orifarm Healthcare Product Development PMO Director 
Experienced IT Business Solutions Manager for the Danish Medicines Agency 
Lab Manager 
Pharmacovigilance & Regulatory Officer 
Senior/lead consultant at Emendo Engineering